HOWLWerewolf Therapeutics, Inc.

$35M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-90.5% YoY

Gross Profit

$71,0003.8% margin

Operating Income

-$74M-3904.2% margin

Net Income

-$71M-3740.8% margin

EPS (Diluted)

$-1.63

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$56M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$127M

Total Liabilities

$54M

Stockholders' Equity

$73M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$20M	-90.5%
Gross Profit	$71,000	$18M	-99.6%
Operating Income	-$74M	-$41M	-81.7%
Net Income	-$71M	-$37M	-88.7%

HOWL FY 2024 Earnings — Werewolf Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena